🇺🇸 FDA
Patent

US 8143252

Tetrahalogenated compounds useful as inhibitors of angiogenesis

granted A61PA61P35/00

Quick answer

US patent 8143252 (Tetrahalogenated compounds useful as inhibitors of angiogenesis) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon Mar 22 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary of the Department of Health and Human Services
Grant date
Tue Mar 27 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 22 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
31
CPC classes
A61P, A61P35/00